This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Technologies and Applications Digital Week
September 27 - 28, 2022
2-day free-to-attend webcast series

September 27 - 28, 2022
2-day free-to-attend webcast series

JOIN SARTORIUS AT ANTIBODY ENGINEERING & THERAPEUTICS DIGITAL WEEK 2022

A global 2-day series that will provide valuable updates, insights and perspectives on bispecific antibodies, targeted antibodies for cancer therapies, the future of biologics, machine learning applications, antibody sequence strategies and more!

Disrupting the immunotherapy field: A novel platform for targeting chronic diseases

11 AM EDT / 4 PM BST / 5 PM CEST

Vaccines have been some of the most successful modalities for disease management around the globe. However, the application of vaccines to treating chronic diseases has been limited due to the challenge of inducing a safe immune response against self-antigens. Instead, passive immunotherapy approaches, like monoclonal antibodies, have become the means to target disease-associated proteins for chronic diseases. Vaxxinity is disrupting this paradigm by developing a novel platform that triggers a safe and specific antibody response against self-antigen, enabling the use of vaccines to treat chronic diseases. The approach is also cost effective and amenable to wide distribution, allowing broader global reach compared to mAb-based treatments. Currently, Vaxxinity has multiple vaccine candidates in clinical trials, including a phase-I alpha-synuclein vaccine for Parkinson’s disease. This presentation will feature an overview of Sartorius’s advanced bioanalytical solutions for vaccine discovery and development, as well as a deep dive into Vaxxinity’s preclinical path to selecting vaccines, including the novel vaccine for Parkinson’s disease.